Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioCryst Pharmaceuticals Inc.

www.biocryst.com

Latest From BioCryst Pharmaceuticals Inc.

Mixed Responses To BioCryst's Oral Phase III HAI Therapy, BCX7353

BioCryst’s BCX7353 could be the first oral therapy to prevent hereditary angioedema attacks, but it might not work in all patients, according to data from the Phase III APeX-2 study.

Immune Disorders Clinical Trials

Finance Watch: Gossamer, Alector And Harpoon Launch First Biopharma IPOs Of 2019

Public Company Edition: Grossing $276m, Gossamer would have been the third-largest biopharma IPO in the US if it had launched last year. Also, recent public company financings include debt and follow-on offerings; and two more firms cut jobs – Capricor and Seres.

Financing Business Strategies

Anticancers, Orphans & The First CAR-Ts: New EU Drug Approvals In 2018

New approvals in the EU were again dominated by oncology drugs in 2018, although medicines for infectious diseases were a close second. The number of orphan drugs more than doubled over the previous year, to 17. There were also some star arrivals in multiple sclerosis, genetic disorders, metabolism and migraine.

Approvals Europe

EU New Drug Approvals 2018: Anticancers, Orphans, The First CAR-Ts – And More

New drug approvals in the EU were again dominated by oncology in 2018, although medicines for infectious diseases came a close second. The number of orphan drugs more than doubled over the previous year, to 17. There were also some key new arrivals in the areas of multiple sclerosis, genetic disorders, metabolism and migraine.
Approvals Europe
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Infectious & Viral Diseases
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • BioCryst Pharmaceuticals Inc.
  • Senior Management
  • Jon P Stonehouse, Pres. & CEO
    Thomas R Staab, SVP, CFO
    William P Sheridan, SVP, CMO
    Lynne Powell, SVP, Chief Commercial Officer
    Yarlagadda S Babu, PhD, SVP, Drug Discovery
    Elliott Berger, PhD, SVP, Reg Affairs
    Carol Ohmstede, PhD, VP, Project Management
    Megan Sniecinski , Chief Bus. Officer
  • Contact Info
  • BioCryst Pharmaceuticals Inc.
    Phone: (919) 859-1302
    4505 Emperor Blvd., Ste. 200
    Durham, NC 27703
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register